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Inactivation of tumor suppressor genes has been frequently observed in gastric carcinogenesis. Our purpose was to
study the involvement of p53, APC, DCC, and Rb genes in gastric carcinoma.
METHOD: Loss of heterozygosity of the p53, APC, DCC and Rb genes was studied in 22 gastric cancer tissues using
polymerase chain reaction; single-strand conformation polymorphism of the p53 gene exons 5-6 and exons 7-8 was studied
using 35S-dATP, and p53 expression was detected using a histological immunoperoxidase method with an anti-p53 clone.
RESULTS AND DISCUSSION: No loss of heterozygosity was observed in any of these tumor suppressor genes;
homozygous deletion was detected in the Rb gene in 23% (3/13) of the cases of intestinal-type gastric carcinoma. Eighteen
(81.8%) cases showed band mobility shifts in exons 5-6 and/or 7-8 of the p53 gene. The presence of the p53 protein was
positive in gastric cancer cells in 14 cases (63.6%). Normal gastric mucosa showed negative staining for p53; thus, the
immunoreactivity was likely to represent mutant forms. The correlation of band mobility shift and the immunoreactivity to
anti-p53 was not significant (P = .90). There was no correlation of gene alterations with the disease severity.
CONCLUSIONS: The inactivation of Rb and p53 genes is involved in gastric carcinogenesis in our environment. Loss
of the Rb gene observed only in the intestinal-type gastric cancer should be further evaluated in association with Helicobacter
pylori infection. The p53 gene was affected in both intestinal and diffuse histological types of gastric cancer.
KEY WORDS: Gastric cancer. APC. DCC. Rb. p53.
Gastric cancer is a heterogeneous
pathology, being classified by Laurén
(1965)1 into 2 general subtypes: intes-
tinal (differentiated) and diffuse (un-
differentiated). Intestinal-type gastric
cancer may or may not be preceded by
preneoplastic lesions; it is more preva-
lent in older individuals and in certain
geographical areas where there is a
high incidence of gastric carcinoma,
such as in Japan.2
The differences between these two
histological subtypes occur also at the
molecular level, suggesting different
genetic pathways. The intestinal-type
gastric carcinoma presents tumor sup-
pressor gene alterations similar to
colorectal tumors and distinct from dif-
fuse-type gastric cancer.3
An accumulation of multiple ge-
netic and epigenetic alterations of
oncogenes, tumor suppressor genes,
DNA repair genes, cell cycle regula-
tors, cell adhesion molecules, and
growth factor/receptor systems are in-
volved throughout the course of the
multistep conversion of normal epithe-
lial cells to clinical gastric cancer.4
In gastric cancer, p53 gene altera-
tions have been observed in both his-
tological subtypes,5 being correlated
with node-positive cancer,6,7 depth of
tumor invasion,8 and poor survival.9,10
The p53 protein is a transcriptional
factor that arrests the cell cycle in the
G1 phase when DNA is damaged11 by
inducing the expression of the p21
protein, an inhibitor of Cdk kinase and
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PCNA.12,13 Thus, damaged DNA can
not replicate, allowing time for the re-
pair system to act.11 If this system fails,
p53 induces apoptosis by
transactivation of the bax gene.14
The loss of heterozygosity (LOH)
and the loss of expression of the DCC
gene have been more frequently found
in the intestinal-type gastric cancer15-
17 and have often been encountered
(35.3%) in gastric cancer in stage III
and IV. Thus, in gastric cancer, LOH of
the DCC gene was a late event associ-
ated with malignant progression.15,18
The DCC gene, located on the long
arm of chromosome 18,19 encodes a
netrin-1 receptor component with func-
tions in cell migration,20 G2/M cell cy-
cle arrest, and apoptosis.21
The mutated APC germline gene on
chromosome 5q21 is responsible for the
inheritance of familial adenomatous
polyposis; in addition, it was
somatically altered in sporadic
colorectal cancer patients.22 In gastric
cancer, the incidence of allelic deletions
of APC was significantly higher in the
intestinal phenotypes than in the dif-
fuse phenotypes.23 Furthermore, APC
down-regulates the proto-oncogene β-
catenin that is critical for intercellular
adhesion and has linked colorectal car-
cinogenesis to the Wnt-signal transduc-
tion pathway.24 Increased β-catenin
mRNA levels were significantly more
frequent in intestinal-type gastric can-
cers as compared with the diffuse-type
gastric cancers. APC gene mutations
found in these cases of intestinal-type
gastric cancer were associated with the
increase of β-catenin mRNA levels.25
Loss of the retinoblastoma (Rb)
gene has been associated with
esophageal tumorigenesis,26 and at a
lower rate to gastric cancer develop-
ment.17 However, more recent reports
have shown that Helicobacter pylori
(H. pylori) infection generated gastric
cancer through p53-Rb tumor-suppres-
sor system mutation and telomerase re-
activation.27 The Rb gene encodes a
nuclear protein that acts as a cell cy-
cle control checkpoint at the G1
phase.28
The purpose of our study was to fur-
ther analyze the involvement of p53,
APC, DCC, and Rb tumor suppressor
genes in gastric carcinoma cases.
MATERIALS AND METHOD
Gastric cancer tissues and corre-
sponding leukocytes were obtained
from 22 patients after surgical treat-
ment during the period of 1996 to
1997 at the Hospital of Clinics, De-
partment of Gastroenterology, and
were immediately frozen in liquid ni-
trogen and stored prior to DNA extrac-
tion. The average age of the patients
(18 men, 4 women) was 63.4 + 14.3
years. The tumors were classified as in-
testinal and diffuse types according to
Láuren1; 13 cases were of the intesti-
nal type and 9 cases were of the dif-
fuse type. The TNM stage grouping
was performed according to the crite-
ria of the Japanese Classification of
Gastric Carcinoma.29
DNA extraction
DNA was extracted from the
thawed cancer tissue and peripheral
leucocytes using a phenol-chloroform
method30 and stored at 4 °C until use.
Polymerase Chain Reaction (PCR)
One microgram or 300 ng of ge-
nomic DNA was used as a template in
a reaction volume of 50 uL, contain-
ing 50 pmol of each primer (Table 1),
200 uM of each dNTP and 2.5 U of
Taq DNA polymerase (Gibco BRL,
Gaithersburg, MD, USA). The PCR was
performed in a 2400 GeneAmp PCR
system (Perkin Elmer, Branchburg, NJ,
USA). Amplification was performed for
35 cycles at an annealing temperature
of 68 °C for APC,31 62 °C for p53,32
55 °C for DCC,31 and 57 °C for Rb-
D13S270.33 The amplification condi-
tions for Rb intron1 were 40 cycles in
2 steps (94 °C for 1 min and 50 °C for
1 min), followed by 1 extension step
at 72 °C for 5 min; inclusion of 10%
dimethyl sulfoxide (DMSO) was nec-
essary for generating the 180 bp frag-
ment.34 A second primer pair that spans
the same locus was used in the cases
where the PCR product was absent
from the carcinoma DNA template
when compared with a strong product
from the paired constitutional DNA
template.
Restriction fragment length poly-
morphism analysis
Products of the PCR (~45 uL) were
digested with 60 U of MspI (DCC)
(Stratagene, La Jolla, CA, USA) and
RsaI (APC) (Stratagene, La Jolla, CA,
USA), 15 U of BamHI (Rb) (Stratagene,
La Jolla, CA, USA), and 8 U of AccII
(p53) (Amersham Life Science, Cleve-
land, OH, USA) at 37 °C overnight.
The DNA fragments were separated by
electrophoresis on 4% low-melting-
point agarose gels. For VNTR, Rb
(D13S270), and after MspI digestion,
PCR products were separated on 3%
low-melting-point agarose gels.
PCR Analysis of Single-Strand Con-
formation Polymorphism
Genomic DNA (300 - 500 ng) was
used as a template in a reaction volume
of 25 µL containing 50 pmol of each
primer (Table 1), 200 µM of
deoxynucleotide triphosphate (dNTP),
35S-dATP (0.5 µL), and 2.5 U of Taq
DNA polymerase (Amersham
Biosciences). Exons 5-6 and 7-8 of the
p53 gene were amplified in 35 cycles
according to the following schedule:
94 °C for 30 s, 63 °C for 50 s, and 72 °C
for 1 min. The elongation step was done
at 72 °C for 10 min. Amplification prod-
ucts were diluted 5-fold in 0.1% SDS,
174
REV. HOSP. CLÍN. FAC. MED. S. PAULO 59(4):172-180, 2004p53 and Rb tumor suppressor gene alterations in gastric cancer
Mattar R et al.
10 mM EDTA and were rediluted 1:2 in
sequencing stop solution (95%
formamide, 20 mM EDTA, 0.05%
bromophenol blue, and 0.05% xylene
cyanol); they were then heated at 90 °C
for 5 min, chilled on ice, and loaded onto
a nondenaturing polyacrylamide gel (6%
acrylamide, 10% glycerol, 1x TBE).
Electrophoresis was carried out at 8 W
at room temperature. After 4 hours of mi-
gration for exons 5-6 and 7 to 9 hours
of migration for exons 7-8, the gels were
dried and subjected to autoradiography
using Kodak T-Mat G/RA film at –80 °C
with an intensifying screen. One sample
of amplification product from blood was
run together with tumor DNA amplifica-
tion products. The conditions have been
previously described, with modifica-
tions.35,36 The primers that were used for
PCR were those according to Tohdo et
al. 1993.37
LSAB-immunoperoxidase
Sequential sections of 3 µm from
formalin-fixed, paraffin-embedded
samples were placed on slides previ-
ously treated with 3-
aminopropyltriethoxy-silane (Sigma,
A-3648, USA). After deparaffinization
in xylene and rehydration in alcohol,
antigen retrieval was performed with
10 mM citric acid pH 6.0 in a pressure
cooker for 4 min. Endogenous peroxi-






monoclonal antibody anti-p53 clone
DO-7 (Dako, M7001, Denmark) in 1%
bovine serum albumin-phosphate buff-
ered solution, was performed for 16 h
at 4 °C. The slides were then incubated
for 30 min at 37 °C with secondary
biotinylated goat anti-mouse/rabbit Ig,
followed by incubation for 30 min at
37 °C with the complex, streptavidin
and biotinylated peroxidase (Dako,







, and dimethyl sul-
phoxide and counterstained with
Harris’ hematoxylin. The samples were
observed with optic microscope by 2
observers (SN and VAFA) and were
scored as previously described by
Harvey38; estimated proportion and in-
tensity scores were added to obtain a
total score that ranged from 0.2 to 8.
A score greater than 2 was used to de-
fine p53 positivity.
Statistics
The statistic analysis was per-
formed with the chi-square and Fisher
exact tests using the SPSS 7.5 for Win-
dows, student version. A P value of
<.05 was considered statistically sig-
nificant.
RESULTS
The results of the analysis of PCR
products for loss of heterozygosity
(LOH) at the Rb, APC, DCC, and p53
loci on 22 gastric cancer tissues (13 of
intestinal type and 9 of diffuse type)
matched with corresponding periph-
eral leukocytes are listed in Table 2.
Heterozygosity was found for APC in
13 of 21 (61.9%) cases, for DCC in 13
of 22 (59%) cases, for p53 in 11of 21
(52.4%) cases, and for Rb in 7 of 19
(36.8%) cases. Those cases that had no
amplification in leukocyte and tumor
DNA for unknown reasons were ex-
cluded from this analysis. No LOH was
observed in these tumor suppressor
genes. Nonetheless, no PCR product
was obtained for the tumor DNA when
compared to the normal DNA at the
DCC gene in 1 patient (CA.6) and at
the Rb gene in 3 patients (CA.6,
CA.11, CA.22), suggesting ho-
mozygous deletion.
To confirm homozygous deletion at
the DCC and Rb genes, a second pair
Table 1 - Primer sets used in polymerase chain reaction analysis for loss of heterozygosity (PCR-LOH) and polymerase chain
reaction analysis for single-strand conformation polymorphism (PCR-SSCP) analysis.
Priming region Amplicon size (bp) Polymorphism type Primer Sequences
APC exon 11 133 Rsa I 5’-GGACTACAGGCCATTGCAGAA-3’
5’-GGCTACATCTCCAAAAGTCAA-3’
p53 exon 4 259 AccII 5’-AATGGATGATTTGATGCTGTCCC-3’
5’-CGTGCAAGTCACAGACTTGGC-3’
DCC* 210-150 VNTR 5’-GATGACATTTTCCCTCTAG-3’
5’-GTGGTTATTGCCTTGAAAAG-3’
DCC 396 MspI 5’-TGCACCATGCTGAAGATTGT-3’
5’-AGTACAACACAAGGTATGTG-3’
Rb intron 1 180 BamHI 5’-CAGGACAGCGGCCCGGAG-3’
5’-CTGCAGACGCTCCGCCGT-3’
Rb D13S270* 104-80 5’- AGTGCCTGGGTATGAACGTG-3’
5’- CTGGAAATGCCTTGGAAGGA-3’
p53 exons 5-6 411 5’-GGAATTCCTCTTCCTACAGTACTCC-3’
5’-GGAATTCAGTTGCAAACCAGACCTCA-3’
p53 exons 7-8 677 5’-GGAATTCTCCTAGGTTGGCTCTGAC-3’
5’-GGAATTCCTGCTTGCTTACCTCGCT-3’
* = Only to confirm homozygous deletion.
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of primers that span the same locus was
used, a variable number of the tandem
repeat markers (VNTR) was used for
the DCC gene, and a microsatellite
marker (D13S270) was used for the Rb
gene. Homozygous deletion was con-
firmed only at the Rb gene (Figure 1).
These 3 cases of the intestinal-type
gastric carcinomas (3/13—23%) with
homozygous deletion at Rb gene were
classified as stage Ia, stage II, and stage
IIIb, respectively.
Since p53 gene alterations are very
frequent in gastric cancer and no al-
lelic loss was detected, we decided to
search for mutations using PCR analy-
sis for single-strand conformation
polymorphism (PCR-SSCP) and p53
protein overexpression using LSAB-
immunoperoxidase. Eighteen (81.8%)
cases of both histological types
showed mobility shifts in exons 5-6
and/or 7-8 of the p53 gene (Figure 2).
The p53 protein expression was posi-
tive in gastric cancer cells in 14 cases
(63.6%). There was no significant cor-
relation of band mobility shift and im-
munoreactivity to anti-p53 (P = .90).
The staining of p53 was never ob-
served in the normal gastric mucosa
adjacent to the tumor tissue; thus, p53
protein immunoreactivity likely indi-
cated mutant forms of the p53 gene.
The correlation of band mobility shifts
and immunoreactivity was not ob-
served in 9 cases. In 7 cases, a mobil-
ity shift was detected in exons 7-8
with negative immunoreactivity to
anti-p53, 4 were 0 + 0 = 0 and 3 cases
were 1p + 1i = 2. The immunoreactiv-
ity to anti-p53 was positive in 2 cases
(2p + 3i = 5; 2p + 1i = 3) with a nega-
tive band mobility shift.
The statistical analysis showed that
there was no correlation of sex, age,
histology, or severity of disease with
mutation and with the immunoreactiv-
ity to anti-p53.
DISCUSSION
To understand the molecular events
of gastric carcinogenesis in our envi-
Table 2 - p53 protein immunoreactivity to anti-p53, band mobility shift by single strand conformation polymorphism
(SSCP) in exons 5-6 and exons 7-8, and analysis of loss of heterozygosity at APC, DCC, p53, and Rb loci in gastric cancer.
Case Age Sex Stage Histology Allred Exons 5-6 Exons  7-8 APC DCC p53 Rb
CA.1 70 M II Intestinal 2p+3i=5 NEG NEG INF H INF INF
CA.2 62 F II Intestinal 0+0=0 NEG POS INF INF INF INF
CA.3 77 M IIIa Intestinal 2p+1i=3 NEG POS H H INF H
CA.4 68 M II Diffuse 5p+3i=8 NEG POS H INF H INF
CA.5 93 F IIIb Intestinal 2p+1i=3 NEG NEG INF INF INF H
CA.6 73 M IIIb Intestinal 5p+3i=8 NEG POS INF H * H HD
CA.7 61 M II Diffuse 5p+2i=7 POS POS INF INF INF H
CA.8 55 M IIIb Intestinal 0+0=0 NEG POS INF H INF INF
CA.9 39 M IIIb Intestinal 1p+1i=2 NEG POS H INF INF H
CA.10 72 M IVa Diffuse 1p+3i=4 POS POS INF H H H
CA.11 59 M II Intestinal 1p+1i=2 NEG NEG INF H H HD
CA.12 76 M IIIa Intestinal 5p+2i=7 POS POS H H H H
CA.13 68 M II Intestinal 2p+2i=4 NEG POS INF INF INF H
CA.14 52 M IIIa Diffuse 4p+3i=7 NEG POS H H H INF
CA.15 72 F II Diffuse 2p+1i=3 POS POS INF INF H H
CA.16 64 M IIIb Diffuse 1p+1i=2 NEG POS INF INF INF H
CA.17 73 M IVa Intestinal 3p+1i=4 NEG POS H INF H INF
CA.18 72 M IIIb Diffuse 3p+1i=4 NEG POS INF INF H NA
CA.19 40 F II Diffuse 0+0=0 NEG NEG H INF H NA
CA.20 49 M II Diffuse 0+0=0 NEG POS NA H NA NA
CA.21 61 M II Intestinal 4p+1i=5 NEG POS H INF INF INF
CA.22 32 M Ia Intestinal 0+0=0 NEG POS INF INF INF HD
POS = band mobility shift positive; NEG = no band mobility shift; INF = informative case with no LOH; H = homozygous (no informative); HD
= homozygous deletion; NA = no amplification in leukocyte and tumor DNA; H* = homozygous for VNTR marker.
Figure 1 - Homozygous deletion at Rb tumor
suppressor genes in gastric cancer. DNA band
sizes are indicated in numbers of base pairs.
N, leukocytes DNA; T, tumor DNA. (A)
Cleavage of 180 bp PCR products by BamHI
results in fragments 130 and 50 bp long. These
three cases (CA.6, CA.11 and CA.22) are
heterozygous; however , both alleles are
deleted (shown by the arrows), confirmed by
microsatellite marker D13S270 (B).
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ronment, the DNA of 22 gastric tumors
paired with corresponding DNA of pe-
ripheral leukocytes were studied for
loss of heterogeneity (LOH) of the p53,
APC, DCC, and Rb genes. These tumor
suppressor genes were chosen for this
study based on previous reports show-
ing that their inactivations have a role
in gastric carcinogenesis.
Loss of heterogeneity at the APC
locus was detected in 87% of primary
gastric carcinomas in both intestinal
and diffuse types in both early and ad-
vanced stages.39 Therefore, LOH at
APC was considered one of the most
prevalent genetic alterations in human
gastric carcinoma, and it occurred at an
early stage of the carcinogenesis and
was not a prognostic factor. Moreover,
Sano et al.40 had observed LOH on
chromosome 5q where the APC gene
is located in 60% of early well-differ-
entiated carcinoma, but not in poorly
differentiated carcinoma.
In our study, no LOH was detected
at the APC locus. Other authors17,41
studying the same polymorphic site
found a low incidence (27% - 30%) of
LOH in gastric cancer. Also in Africa,
where the frequency of gastric cancer
is low as it is in Brazil, only 1 patient
presented LOH in the 5q region.42 Fur-
thermore, in gastric cancer patients
from north-central Italy, no intragenic
mutations were found in APC codons
686 through 1693, and allelic loss was
detected in loci near APC.43
These authors argued that epide-
miologic studies have not observed a
higher risk of gastric cancer in patients
with inherited familial adenomatous
polyposis. Fundic gland polyps are the
most common gastric lesion in famil-
ial adenomatous polyposis and are
generally believed to have little or no
potential for malignant transformation
in the population at large. The devel-
opment of high-grade dysplasia or gas-
tric adenocarcinoma associated with
diffuse fundic gland polyposis was de-
scribed in a few cases of familial
adenomatous polyposis.44 Gastric-type
adenomas were less likely to show
high-grade dysplasia and adenocarci-
noma and were found in 10 patients
with familial adenomatous polyposis.45
High frequencies of allelic dele-
tions affecting the DCC locus have
been previously described to occur in
30%17 to 60%16 of cases of both types
of gastric cancer15 and more often in
advanced (50%) than in early (14.3%)
disease. Only 1 case in the present
study (CA.6) showed what seemed to
be homozygous deletion at the DCC
gene by RFLP; however, with another
pair of primers, a region of the DCC
gene was amplified. Thus, the possibil-
ity of homozygous deletion was ex-
cluded. Since the frequency of DCC
loss is higher in advanced disease and
more frequent in the intestinal type, we
were expecting that at least in the 5
cases that had advanced intestinal-
type gastric cancer and were informa-
tive for DCC gene, loss would be
found.
Homozygous deletion at the Rb
gene was detected in 3 (3/13–23%)
cases of the intestinal-type gastric can-
cer, which seems to be an early event,
since 2 of these patients had initial dis-
ease (stage Ia and stage II). The inacti-
vation of the Rb gene by mutation or
loss has been considered an important
genetic alteration in esophageal car-
cinogenesis.26, 31 Our data suggest that
Rb gene inactivation may be involved
in the development and/or progression
of intestinal-type gastric cancer.
Homozygous deletions are thought
to be the result of 2 events: the loss of
a larger chromosomal region and the
independent loss of a considerably
smaller area.46 In previous reports, ho-
mozygous deletion was described in a
variety of cancers as a mechanism of
total gene inactivation, and the pres-
ence of at least 1 tumor suppressor
gene within the deleted region was
suggested.47-50
A higher prevalence (30%) of Rb-
LOH in both histological types of gas-
tric cancer was found by other au-
thors.17 A more recent report51 showed
that the mRNA levels of Rb and p53
in gastric cancer tissues were both sig-
nificantly lower than were those in
their noncancerous tissue samples.
Figure 2 - Polymerase chain reaction analysis for single-strand conformation polymorphism
(PCR-SSCP) analysis of gastric cancer tissues and leukocytes. (A) Band mobility sift in exons 5-
6 of the p53 gene indicated by arrow in three cases. (B) All cases shown are presenting band
mobility shift in exons 7-8 of the p53 gene. N, leukocytes DNA; T, tumor DNA.
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These studies indicate that the sup-
pression of both Rb and p53 may be
associated with the tumorigenesis of
the stomach.
Loss of heterozygosity on chromo-
some 17p (p53 locus) and mutation of
the p53 gene have been observed in
more than 60% of gastric carcinomas,
regardless of the histological type,40
and have been correlated with short
survival times.9 Surprising, no LOH at
the p53 gene was observed in our
cases. One possible explanation for the
fact that we did not find LOH at p53
gene may be that this gene may be al-
tered through another mechanism,
such as point mutation. To search for
p53 gene mutations, we decided to use
PCR-SSCP and to correlate with immu-
noreactivity to anti-p53. The half-life
of wild-type p53 is short, around 20 to
30 minutes; consequently, p53 protein
expression usually is negative in nor-
mal tissues. Mutations render the p53
protein to be a more stable compound
with a longer half-life (1.5 - 7 h).52
Thus, p53 protein overexpression is
likely to represent mutant forms.53
In the literature, the authors usually
employ 32P-dCTP for PCR-SSCP35,36;
however, 32P is a high-energy β parti-
cle emitter, so we decided to try the
low-energy β particle emitter, 35S-
dATP. The bands were easily visual-
ized in dried gels exposed at –80º C for
at least 3 days. Thus, the use of 35S-
dATP was more advantageous than 32P-
dATP, since it lowered the risk for the
personnel of the lab.
Following PCR-SSCP, band mobil-
ity shifts were observed mainly in
exons 7-8 (86.36%) that encompasses
codons 225 to 326. Other authors54
studying p53 in gastric cancer also
found a predominance of mutations in
exons 7-8 (70%).
Non-missense mutations or
frameshifts could explain negative im-
munoreactivity with band mobility
shifts in 7 cases. Moreover, analyzing
the Allred criteria only 4 were truly
negative 0+0=0, and 3 cases were
1p+1i=2 (considered negative). Allred
2 should be better evaluated and, per-
haps, considered as positive for p53
expression as determined by immuno-
histochemistry. Seta et al., 199854
found a p53 mutation in 2 cases of
gastric cancer with less than 25% of
cells positive (+) by immunohisto-
chemistry. Assuming Allred 2 to be
positive for p53, the agreement of im-
munohistochemistry and PCR-SSCP
would be 72.7%.
In 2 cases that had immunoreactiv-
ity to anti-p53 and most probably
harbored mutation in the p53 gene,
PCR-SSCP was unable to detect mu-
tation. A discrepancy between results
by PCR-SSCP and DNA sequencing
has been reported in the literature. In
MKN-7 and MKN-28 gastric cancer
cell lines, p53 gene mutations were not
detected by PCR-SSCP36; however,
point mutations at codons 278 and
251, respectively, were found by
cDNA sequencing.53
In conclusion, the inactivation of
p53 is involved in the development
and/or progression of both diffuse and
intestinal types of gastric cancer. How-
ever, loss of the Rb gene plays role
only in the intestinal-type gastric can-
cer progression. It has been suggested
that H. pylori infection initiates gas-
tric cancer through p53-Rb tumor-sup-
pressor system mutation and
telomerase reactivation.27 Even though
the incidence of H. pylori in the nor-
mal population of Brazil is high (80%),
the association of H. pylori infection
and gastric cancer has been observed
exclusively with the intestinal type (P
= .008)55. Further studies are needed to
demonstrate the direct involvement of
H. pylori in p53 and Rb gene inacti-
vation in our cases of gastric cancer.
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RESUMO
MATTAR R e col. Alterações dos genes
supressores tumorais p53 e Rb no
câncer gástrico. Rev. Hosp. Clín.
Fac. Med. S. Paulo 59(4):172-180,
2004.
A inativação de genes supressores
tumorais tem sido freqüentemente ob-
servada na carcinogênese gástrica. O
nosso objetivo foi estudar o envol-
vimento dos genes p53, APC, DCC e
Rb no câncer gástrico.
MÉTODO: Vinte e dois casos de
câncer gástrico foram estudados por
PCR-LOH (reação de polimerase em
cadeia- perda de alelo heterozigoto)
dos genes p53, APC, DCC e Rb; e por
PCR-SSCP (reação de polimerase em
cadeia- polimorfismo de conformação
de cadeia única) dos exons 5-6 e exons
7-8 do gene p53, empregando 35S-




Perda de alelo heterozigoto não foi de-
tectada nos genes estudados; deleção
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homozigótica foi observada no gene
Rb em 23% (3/13) dos casos de cân-
cer gástrico do tipo intestinal. Desvio
de motilidade de banda nos exons 5-6
e/ou exons 7-8, indicando mutação do
gene p53 foi encontrada em 18 casos
(81.8%). A expressão de p53 foi posi-
tiva nas células de câncer gástrico em
14 casos (63.6%). A mucosa gástrica
normal não corou com anti-p53, por-
tanto, a reatividade imune deve repre-
sentar formas mutantes. A correlação
de desvio de motilidade de banda e
expressão imune de p53 não foi
significante (p=0.90). Não houve cor-
relação entre as alterações genéticas e
a extensão da doença.
CONCLUSÃO: A inativação dos
genes p53 e Rb tem papel na carci-
nogênese gástrica no nosso meio. A
perda do gene Rb observada apenas no
câncer gástrico do tipo intestinal deve
ser avaliada posteriormente em associ-
ação com infecção pelo Helicobacter
pylori. O gene p53 estava afetado em
ambos os tipos histopatológicos.
UNITERMOS: Câncer gástrico.
p53. APC. DCC. Rb.
REFERENCES
1. Laurén P. The two histological main types of gastric carcinoma:
diffuse and so-called intestinal-type. Acta Pathol Microbiol
Scand 1965;64:31-49.
2. Hirohashi S, Sugimura T. Genetic alterations in human gastric
cancer. Cancer Cells 1991;3:49-52.
3. Tahara E. Molecular mechanism of stomach carcinogenesis. J
Cancer Res Clin Oncol 1993;119:265-72.
4. Yasui W, Yokozaki H, Fujimoto J, Naka K, Kuniyasu H, Tahara E.
Genetic and epigenetic alterations in multistep carcinogenesis
of the stomach. J. Gastroenterol 2000;35:111-5.
5. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor
gene expression correlates with gastric cancer prognosis. J
Pathol 2003;200:39-46.
6. Maehara Y, Tomoda M, Hasuda S, Kabashima A, Tokunaga E,
Kakeji Y, et al. Prognostic value of p53 protein expression for
patients with gastric cancer- a multivariate analysis. Br J Cancer
1999;79:1255-61.
7. Baldus SE, Schneider PM, Monig SP, Zirbes TK, Fromm S, Meyer
W, et al. p21/waf1/cip1 in gastric cancer: associations with
histopathological subtypes, lymphonodal metastasis, prognosis
and p53 status. Scand J Gastroenterol 2001;36:975-80.
8. Kataoka M, Okabayashi T, Johira H, Nakatani S, Nakashima A,
Takeda A, et al. Aberration of p53 and DCC in gastric and
colorectal cancer. Oncol Rep 2000; 7:99-103.
9. Lee WJ, Shun CT, Hong RL, Wu MS, Chang KJ, Chen KM.
Overexpression of p53 predicts shorter survival in diffuse
type-gastric cancer. Br J Surg 1998;85:1138-42.
10. Kubicka S, Claas C, Staab S, Kuhnel F, Zender L, Trautwein C, et
al. p53 mutation pattern and expression of c-erbB2 and c-met
in gastric cancer: relation to histological subtypes, Helicobacter
pylori infection, and prognosis. Dig Dis Sci 2002;47:114-21.
11. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW.
Participation of p53 protein in the cellular response to DNA
damage. Cancer Res 1991;51:6304-11.
12. Chen J, Jackson PK, Kirschner MW, Dutta A. Separate domains of
p21 involved in the inhibition of Cdk kinase and PCNA. Nature
1995;374:386-8.
13. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of
cyclin-dependent kinases controls DNA replication by
interaction with PCNA. Nature 1994;369:574-8.
14. Miyashita T, Reed JC. Tumor suppressor p53 is a direct
transcriptional activator of the human bax gene. Cell
1995;80:293-9.
15. Fang DC, Jass JR,Wang DX. Loss of heterozygosity and loss of
expression of the DCC gene in gastric cancer. J Clin Pathol
1998;51:593-6.
16. Uchino S, Tsuda H, Noguchi M, Yokota J, Terada M, Saito T, et
al. Frequent loss of heterozygosity at the DCC locus in gastric
cancer. Cancer Res 1992;52:3099-102.
17. Cho JH, Noguchi M, Ochiai A, Hirohashi S. Loss of heterozygosity
of multiple tumor suppressor genes in human gastric cancers
by polymerase chain reaction. Lab Invest 1996;74:835- 41.
18. Candusso ME, Luinetti O, Villani L, Alberizzi P, Klersy C, Fiocca
R, et al. Loss of heterozygosity at 18q21 region in gastric
cancer involves a number of cancer-related genes and correlates
with stage and histology, but lacks independent prognostic
value. J Pathol 2002;197:44-50.
19. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert
JM, et al. Identification of a chromosome 18q gene that is
altered in colorectal cancers. Science 1990;247:49-56.
20. Cooper HM, Gad JM, Keeling SL. The Deleted in Colorectal
Cancer netrin guidance system: a molecular strategy for
neuronal navigation. Clin Exp Pharmacol Physiol
1999;26:749-51.
21. Chen YQ, Hsieh JT, Yao F, Fang B, Pong RC, Cipriano SC, et al.
Induction of apoptosis and G2/M cell cycle arrest by DCC.
Oncogene 1999;18:2747-54.
22. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, et
al. Mutations of chromosome 5q21 genes in FAP and colorectal
cancer patients. Science 1991;253:665-9.
179
REV. HOSP. CLÍN. FAC. MED. S. PAULO 59(4):172-180, 2004 p53 and Rb tumor suppressor gene alterations in gastric cancer
Mattar R et al.
23. Wu LB, Kushima R, Borchard F, Molsberger G, Hattori T.
Intramucosal carcinomas of the stomach: phenotypic
expression and loss of heterozygosity at microsatellites linked
to the APC gene. Pathol Res Pract 1998;194:405-11.
24. Kolligs FT, Bommer G, Goke B. Wnt/beta-catenin/tcf signaling: a
critical pathway in gastrointestinal tumorigenesis. Digestion
2002;66:131-44.
25. Ebert MP, Fei G, Kahmann S, Muller O, Yu J, Sung JJ, et al.
Increased beta-catenin mRNA levels and mutational alterations
of the APC and beta-catenin gene are present in intestinal-type
gastric cancer. Carcinogenesis 2002;23:87-91.
26. Xing EP, Yang GY, Wang LD, Shi ST, Yang CS. Loss of
heterozygosity of the Rb gene correlates with pRb protein
expression and associates with p53 alteration in human
esophageal cancer. Clin Cancer Res 1999;5:1231-40.
27. Lan J, Xiong YY, Lin YX, Wang BC, Gong LL, Xu HS, et al.
Helicobacter pylori infection generated gastric cancer through
p53-Rb tumor-suppressor system mutation and telomerase
reactivation. World J Gastroenterol 2003 ;9:54-8.
28. Strobeck MW, Knudsen KE, Fribourg AF, DeCristofaro MF,
Weissman BE, Imbalzano AN, et al. BRG-1 is required for RB-
mediated cell cycle arrest. Proc Natl Acad Sci USA
2000;97:7748-53.
29. Japanese Research Society for Gastric Cancer - Japanese
classification of gastric carcinoma. Tokyo: Kanehara & Co.
Ltda., 1995.
30. Sambrook J, Fritsch EF, Maniatis T. Isolation of high-molecular-
weight DNA from mammalian cells. In:Molecular Cloning- A
Laboratory Manual, 2nd ed. New York:Cold Spring Harbor
Laboratory, 1989. p. 9.14-9.19
31. Huang Y, Boynton RF, Blount PL, Silverstein RJ, Yin J, Tong Y, et
al. Loss of heterozygosity involves multiple tumor suppressor
genes in human esophageal cancers. Cancer Res 1992;52:6525-
30.
32. de la Calle-Martin O, Fabregat V, Romero M, Soler J, Vives J,
Yague J. AccII polymorphism of the p53 gene. Nucleic Acids
Res 1990;18:4963.
33. Goto A, Kanda H, Ishikawa Y, Matsumoto S, Kawaguchi N,
Machinami R, et al. Association of loss of heterozygosity at
the p53 locus with chemoresistance in osteosarcomas. Jpn J
Cancer Res 1998;89:539-47.
34. Bookstein R, Lai CC, To H, Lee WH. PCR-based detection of a
polymorphic BamHI site in intron 1of the human
retinoblastoma (RB) gene. Nucleic Acids Res 1990;18:1666.
35. Mazars R, Pujol P, Maudelonde T, Jeanteur P, Theillet C. p53
mutations in ovarian cancer: a late event? Oncogene
1991;6:1685-190.
36. Yamada Y, Yoshida T, Hayashi K, Sekiya T, Yokota J, Hirohashi S,
et al. p53 gene mutations in gastric cancer metastases and in
gastric cancer cell lines derived from metastases. Cancer Res
1991;51:5800-05.
37. Tohdo H, Yokozaki H, Haruma K, Kajiyama G, Tahara E. p53
gene mutations in gastric adenomas. Virchows Arch B Cell
Pathol 1993;63:191-5.
38. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor
status by immunohistochemistry is superior to the ligand-
binding assay for predicting response to adjuvant endocrine
therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
39. Sanz-Ortega J, Sanz-Esponera J, Caldes T, Gomez de la Concha
E, Sobel ME, Merino MJ. LOH at the APC/MCC gene (5q21)
in gastric cancer and preneoplastic lesions. Prognostic
implications. Pathol Res Pract 1996;192:1206-10.
40. Sano T, Tsujino T, Yoshida K, Nakayama H, Haruma K, Ito H, et
al. Frequent loss of heterozygosity on chromosomes 1q, 5q,
and 17p in human gastric carcinomas. Cancer Res 1991;
51:2926-31.
41. Semba S, Yokozaki H, Yamamoto S, Yasui W, Tahara E.
Microsatellite instability in precancerous lesions and
adenocarcinomas of the stomach. Cancer 1996;77:1620-27.
42. Chetty R, Naidoo R, Tarin M, Sitti C. Chromosome 2p, 3p, 5q and
18q status in sporadic gastric cancer. Pathology 2002;34:275-
81.
43. Powell SM, Cummings OW, Mullen JA, Asghar A, Fuga G, Piva P,
et al. Characterization of the APC gene in sporadic gastric
adenocarcinomas. Oncogene 1996;12:1953-9.
44. Hofgartner WT, Thorp M, Ramus MW, Delorefice G, Chey WY,
Ryan CK, et al. Gastric adenocarcinoma associated with fundic
gland polyps in a patient with attenuated familial adenomatous
polyposis. Am J Gastroenterol 1999;94:2275-81.
45. Abraham SC, Montgomery EA, Singh VK, Yardley JH, Wu TT.
Gastric adenomas: intestinal-type and gastric-type adenomas
differ in the risk of adenocarcinoma and presence of
background mucosal pathology. Am J Surg Pathol
2002;26:1276-85.
46. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT,
Rozenblum E, et al. DPC4, a candidate tumor-suppressor gene
at 18q21.1. Science 1996;271:350-3.
47. Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M, Koeffler
HP. Homozygous deletions of the p15 (MTS2) and p16
(CDKN2/MTS1) genes in adult T-cell leukemia. Blood
1995;85:2699-704.
48. Hahn SA, Hoque AT, Moskaluk CA, da Costa LT, Schutte M,
Rozenblum E, et al. Homozygous deletion map at 18q21.1 in
pancreatic cancer. Cancer Res 1996;56:490-4.
49. Sundaresan V, Chung G, Heppell-Parton A, Xiong J, Grundy C,
Roberts I, et al. Homozygous deletions at 3p12 in breast and
lung cancer. Oncogene 1998;17:1723-9.
50. Chandramohan SI, Shuster M, Bockmühl U, Thakker N, Shah P,
Toomes C, et al. Frequent allelic loss and homozygous deletion
in chromosome band 8p23 in oral cancer. Int J Cancer
1999;80:25-31.
51. Chen YJ, Shih LS, Chen YM. Quantitative analysis of CDKN2,
p53 and retinoblastoma mRNA in human gastric carcinoma.
Int J Oncol 1998;13:249-54.
52. Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein
B, et al. Mutant p53 DNA clones from human colon carcinomas
cooperate with ras in transforming primary rat cells: a
comparison of the hot spot mutant phenotypes. Cell Growth
Different 1990;1;571-80.
180
REV. HOSP. CLÍN. FAC. MED. S. PAULO 59(4):172-180, 2004p53 and Rb tumor suppressor gene alterations in gastric cancer
Mattar R et al.
53. Mattar R, Yokozaki H, Yasui W, Ito H, Tahara E. p53 gene mutations
in gastric cancer cell lines. Oncol. (Life Sci. Adv.) 1992;11:7-
12.
54. Seta T, Imazeki F, Yokosuka O, Saisho H, Suzuki T, Koide Y, et al.
Expression of p53 and p21waf1/cip1 proteins in gastric and
esophageal cancers: comparison with mutations of the p53
gene. Dig Dis Sci 1998;43(2):279-89.
55. Mattar R, Silva FM, Birbojm I, Zilberstein B, Gama-Rodrigues JJ.
Helicobacter pylori infection: a risk factor for gastric cancer?
a serological study. Proceedings of the 5th International Gastric
Cancer. 2003. p.17.
